Depression

Study also suggests link between postpartum depression and insomnia.

Psychiatric Times featured a wide variety of psychiatric issues in this year’s CMEs.

Research identifies common reasons and coping mechanisms for depression that increases during the holidays.

Caplyta is now FDA-approved for depressive episodes from bipolar I and II.

Data from a clinical program evaluating the efficacy and safety of zuranolone was presented at the American College of Neuropsychopharmacology Congress. What new developments did they share?

Research also shows increased prevalence of social risks and unmet social needs.

How can transcranial magnetic stimulation help patients with treatment-resistant depression?

Treatment-resistant depression: how to diagnose, what treatment options are available, and how to best help patients.

What is the connection between inflammation and mood disorders?

How can we improve treatment response? Look to the patient.

Loss and suffering can be hard for both patient and provider. Here’s what we know, what we need to learn, and how to protect yourself as a clinician.

What's new and noteworthy in children and adolescent psychiatry?

Results suggest that psilocybin therapy may prove to be helpful in improving quality of life for patients with cancer.

Larger cities may provide a protective buffer against developing depression. 

Lisa Harding, MD, and Angelos Halaris, MD, PhD, APA, ACNP, CINP, give advice to any clinicians considering the use of intranasal esketamine for treatment resistant depression.

Drs Harding and Halaris review the requirements health care settings must follow in order to procure, prescribe, and dispense intranasal esketamine as treatment resistant depression therapy.

Two psychiatrists discuss the importance of intranasal esketamine having a Risk Evaluation and Mitigation Strategy (REMS) and how that impacts treatment for treatment resistant depression.

Drs Harding and Halaris evaluate the phase 3 TRANSFORM trial that studied intranasal esketamine as a therapy option for treatment resistant depression.

Two experts examine the impact of targeting the glutamatergic system as therapy for treatment resistant depression.

Lisa Harding, MD, and Angelos Halaris, MD, PhD, APA, ACNP, CINP, discuss their thoughts on starting treatment with intransal esketamine and what to expect.

Two psychiatrists review the case of 42-year-old female patient with a treatment resistant depression diagnosis that was prescribed intranasal esketamine.

Drs Harding and Halaris provide an overview of treatment resistant depression, including prevalence and determining a diagnosis.

Lisa Harding, MD, and Angelos Halaris, MD, PhD, APA, ACNP, CINP, review a case of a 26-year-old male patient who was recently diagnosed with treatment resistant depression

New Drug Application to be submitted for MDD in late 2022, with separate filing for PPD planned for early 2023. 

How to regulate circadian rhythms and regulate mood using dark therapy.